Viropro Inc. (VPRO)

Overview

Viropro Inc. is a prominent player in the biopharmaceutical industry, focusing on the contract research, development, and manufacturing of biotherapeutic proteins for treating various diseases. With its subsidiaries, Viropro operates across multiple stages of drug development ranging from pre-clinical studies to Phase I, II, and III clinical trials. The company specializes in the production of biologics, including biosimilars, catering to a wide range of illnesses such as cancer, diabetes, hepatitis, and multiple sclerosis. Headquartered in San Jose, California, and with operational facilities in Canada, the United Kingdom, and Malaysia, Viropro has established a global footprint. Furthermore, its collaboration with Oncobiologics, Inc. highlights its commitment to expanding its portfolio and leveraging strategic partnerships to manufacture and commercialize monoclonal antibody products. As a subsidiary of Alpha Biologics Limited, Viropro Inc. is positioned to leverage advanced technologies and expertise in biomanufacturing for the dynamic biotech and biopharmaceutical sectors.

Products and Services

• Bioprocessing for Therapeutic Proteins:

  Viropro specializes in the contract research, development, and manufacture of biotherapeutic proteins aimed at the treatment of various diseases. Utilizing cutting-edge bioprocessing techniques, the company produces high-quality biologics, including biosimilars, for an array of medical conditions like cancer, diabetes, hepatitis, and multiple sclerosis.

• Mammalian Cell Proteins Supply:

  The company provides its clients with an extensive supply of mammalian cell proteins, including monoclonal antibodies and recombinant proteins. These cell-derived products are critical for the development and manufacture of biotherapeutic drugs and play a vital role in the treatment of numerous diseases.

• Cloning and Sequencing Services:

  Viropro offers comprehensive cloning and sequencing services as part of its contractual research activities. This includes the development, validation, and production of biopharmaceutical products and sub-products, utilizing innovative technologies and methodologies to ensure high fidelity and efficacy.

• Manufacturing and Commercial Collaboration:

  The collaboration agreement with Oncobiologics, Inc. underscores Viropro's capability and commitment to manufacturing and commercializing monoclonal antibody products. This partnership exemplifies the company's strategic approach to expanding its product offerings and enhancing its manufacturing capabilities.